Undersea Hyperb Med. 2010 Mar-Apr;37(2):101-5.

Hyperbaric oxygen therapy and age-related macular degeneration.

Source

Retina Associates of South Florida, Margate, Florida, USA. JWEISSMD@aol.com

Abstract

Age-related macular degeneration (AMD) is a significant cause of visual loss in the United States and Western Europe. As the population ages, the prevalence rate of advanced AMD is expected to double by 2030. A one-hour session of hyperbaric oxygen therapy (HBO2) was used to treated a group of 14 patients with advanced AMD. Eight patients were treated at 1.75 ATA, and six patients were treated at 1.5 ATA for one hour. Significant improvements in visual acuity and/or visual field, with improvements in the activities of daily living were observed.

Comment in

Age-related macular degeneration and hyperbaric oxygen. [Undersea Hyperb Med. 2010]
Age-related macular degeneration and hyperbaric oxygen.Worth ER, Carver JA. Undersea Hyperb Med. 2010 Sep-Oct; 37(5):375; author reply 376-8.

PMID:: 20462142; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Publication Types

Case Reports

MeSH Terms

LinkOut - more resources

Full Text Sources

ProQuest

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. [Arch Ophthalmol. 1999]
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
[No authors listed]Arch Ophthalmol. 1999 Oct; 117(10):1329-45.
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. [Arch Ophthalmol. 2001]
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Age-Related Eye Disease Study Research Group. Arch Ophthalmol. 2001 Oct; 119(10):1417-36.
Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. [Ophthalmology. 2004]
Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community.
Evans JR, Fletcher AE, Wormald RP. Ophthalmology. 2004 Mar; 111(3):513-7.
Review How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? [Br J Ophthalmol. 2003]
Review How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?
Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. Br J Ophthalmol. 2003 Mar; 87(3):312-7.
Review Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. [Surv Ophthalmol. 2005]
Review Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.
Slakter JS, Stur M. Surv Ophthalmol. 2005 May-Jun; 50(3):263-73.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Hyperbaric oxygen therapy and age-related macular degeneration.
Hyperbaric oxygen therapy and age-related macular degeneration.
Undersea Hyperb Med. 2010 Mar-Apr ;37(2):101-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: